Type B - Glaukos Corporation (GKOS) 20261102 Stock Analysis

📅 Glaukos Key Upcoming Events

• November 04, 2026 S&P MidCap 400 Index Inclusion (Confirmed)
  • Description: Glaukos is scheduled to replace Okta in the S&P MidCap 400, moving from the S&P SmallCap 600. Index-linked portfolio rebalancing may temporarily increase trading activity, although index inclusion does not independently improve operating fundamentals.
• February 24, 2027 Q4 and Full-Year 2026 Earnings Release (Estimated)
  • Description: This provisional date reflects Glaukos’s historical late-February annual reporting pattern. The company has not confirmed the release date, which may change. Investors will assess whether full-year revenue reaches management’s $775 million to $785 million guidance and whether the preliminary $1 billion 2027 revenue outlook remains achievable.

🏢 Step 1: Glaukos Company Overview & Business Model

Q1-A1. What is Glaukos?

• Company Name (Ticker): Glaukos Corporation (GKOS)
• Sector: Healthcare
• Exchange: NYSE
• Founded: 1998 (exact founding date not established)
• Listing Date: June 25, 2015
• Fiscal Year End: December
• Headquarters: United States, Aliso Viejo, California
• CEO: Thomas W. Burns (Founder Status: No; CEO since 2002)
• Market Cap: $14.06B
• Shares Outstanding: 59.17M
• Current Price: $237.60
• Annual Dividend Yield: ➖ Not applicable
• Ex-dividend Date: ➖ Not applicable
• As-of: November 02, 2026 (ET)

Q1-A2. How Does Glaukos Make Money?

• Ophthalmic Device and Pharmaceutical Sales: Glaukos develops and commercializes medical devices, sustained-release pharmaceutical treatments, and corneal therapies for ophthalmologists and eye-care facilities treating glaucoma and corneal disorders.
• Glaucoma Treatment Franchise: The iStent family consists of implantable micro-invasive glaucoma surgery devices. The iDose TR platform delivers sustained glaucoma medication directly inside the eye, reducing dependence on daily topical medication.
• Corneal Cross-Linking Franchise: Glaukos sells pharmaceutical products and treatment systems for corneal cross-linking, including Photrexa and Epioxa, targeting keratoconus and other corneal disorders.
• Commercialization Economics: Revenue depends primarily on treatment adoption, procedure volumes, product pricing, reimbursement coverage, physician training, and distribution penetration. The business is not subscription software; product utilization and reimbursement-supported procedures drive recurring demand.
• Economic Transition: Glaukos is evolving from a specialized ophthalmic device manufacturer toward a broader therapeutic platform with multiple high-value device and pharmaceutical franchises.

Q1-A3. Glaukos’s Revenue Segments & Core Income Sources

• U.S. Glaucoma: Q3 2026 revenue was $118.60M, representing approximately 56.2% of consolidated revenue. Sales increased 47% YoY, supported by interventional glaucoma adoption and iDose TR commercialization.
• International Glaucoma: Q3 2026 revenue was $33.36M, approximately 15.8% of consolidated revenue. Sales increased 13.3% YoY, reflecting continued international procedure demand but slower growth than in the United States.
• Corneal Health: Q3 2026 revenue was approximately $59.00M, representing 28.0% of consolidated revenue. Sales increased 154% YoY, making it the fastest-growing major franchise as Epioxa contributed to the expansion.
• Consolidated Mix: The three franchises together generated approximately $210.96M against reported total revenue of $211.03M. The small difference reflects rounding.
• Growth Concentration: The U.S. glaucoma business remains the principal revenue contributor, while corneal health offers the strongest incremental growth opportunity. This combination reduces reliance on a single treatment franchise but increases dependence on successful product launches.

Q1-A4. Who Are Glaukos’s Competitors?

• Direct Glaucoma Competitors: Alcon, AbbVie, and other ophthalmic device and pharmaceutical companies compete through surgical glaucoma technologies, drug therapies, and established ophthalmologist relationships.
• Corneal Treatment Competition: Traditional epithelium-off corneal cross-linking procedures compete with Epioxa’s epithelium-on treatment approach. Glaukos also faces competition from other ophthalmic treatment technologies and prospective alternative therapies.
• Legacy Treatment Disruption: Conventional daily prescription eye drops face competition from sustained-release approaches such as iDose TR, which aim to reduce treatment-adherence problems.
• First-Mover Position: Glaukos pioneered commercially important micro-invasive glaucoma surgery technologies and has a meaningful history of establishing new interventional treatment categories.
• Competitive Limitations: Clinical adoption, reimbursement, surgeon preferences, product safety, and competing technologies prevent the company from exercising unrestricted pricing power.

Q1-A5. What Problem Does Glaukos Solve?

• Glaucoma Medication Adherence: Chronic glaucoma patients frequently require ongoing medication, and inconsistent administration can undermine intraocular pressure management. Sustained-release treatments reduce reliance on daily self-administered drops.
• Surgical Treatment Burden: Traditional glaucoma surgery can involve greater invasiveness and recovery requirements. Micro-invasive devices offer selected patients an alternative treatment pathway.
• Keratoconus Treatment Burden: Conventional epithelium-off corneal cross-linking requires removal of the corneal epithelium. Epioxa offers an FDA-approved incision-free, epithelium-on pharmaceutical alternative.
• Clinical and Economic Value: If outcomes and durability remain favorable, less burdensome treatment approaches can improve patient acceptance and create meaningful revenue opportunities for ophthalmology practices.
• Adoption Constraint: Better treatment convenience does not guarantee commercial dominance. Physicians and payers must accept the clinical evidence, costs, reimbursement arrangements, and treatment workflow.

Q1-A6. Glaukos Key Milestones: Past 12 Months

• January 2026 FDA Approval of iDose TR Re-Administration Labeling Supplement
  • Description: The expanded labeling permits unlimited re-administration in patients maintaining a healthy cornea, strengthening the potential lifetime treatment opportunity for the iDose platform.
• July 29, 2026 Q2 2026 Earnings Release
  • Description: Glaukos reported record revenue of $185.6M, up 50% YoY, and raised its annual revenue guidance to $680M-$700M, reflecting accelerating product adoption.
• October 07, 2026 Positive Three-Year Epioxa Clinical Extension Results
  • Description: Long-term follow-up demonstrated sustained corneal-shape improvements, meaningful visual-acuity gains, and a favorable safety profile, supporting Epioxa’s clinical differentiation.
• October 2026 Positive iDose TR Phase 4 Clinical Results
  • Description: A randomized trial evaluating iDose TR alongside cataract surgery demonstrated clinically meaningful intraocular pressure reductions and a favorable safety profile, supporting further adoption opportunities.
• October 28, 2026 Q3 2026 Earnings Release
  • Description: Glaukos reported record quarterly revenue of $211.0M, 58% YoY growth, GAAP net income of $2.0M, and non-GAAP EPS of $0.47. It increased 2026 revenue guidance to $775M-$785M and introduced preliminary 2027 revenue guidance of $1.00B.

Q1-A7. Step 1 Key Takeaways

• Step 1 Summary: Glaukos operates differentiated ophthalmic device and pharmaceutical franchises addressing meaningful clinical needs. Strong iDose TR adoption, Epioxa commercialization, accelerating revenue, and improving profitability have materially strengthened its growth outlook, although reimbursement and execution remain essential.

🌲 Step 2: Glaukos’s Economic Moat, Market Size & Scalability

Q2-A1. Does Glaukos Have a Durable Economic Moat?

• Proprietary Technology: Glaukos benefits from established intellectual property, clinical development experience, implantable device engineering, and specialized sustained-release pharmaceutical technologies.
• Regulatory Barriers: FDA approval requirements, clinical trials, manufacturing validation, and post-approval surveillance create meaningful obstacles for potential entrants.
• Physician Relationships: Surgeon familiarity, training requirements, and established treatment protocols create adoption advantages for proven products.
• Switching Costs: Physician training and clinical workflow integration support retention, although ophthalmologists retain the ability to adopt competing products.
• Network Effects: Traditional platform network effects are limited. Increasing procedure volumes may improve physician experience and market awareness, but product value does not automatically rise with the number of users.
• Pricing Power: Differentiated clinical outcomes may support premium pricing, subject to insurer reimbursement, healthcare procurement pressure, and competing treatment alternatives.
• Durability Assessment: The moat is meaningful because it combines clinical evidence, regulatory approvals, manufacturing expertise, and commercial distribution rather than relying on a single patent.

Q2-A2. How Big Is Glaukos’s Market? (TAM)

• Addressable Market: Glaukos participates in glaucoma surgery, sustained-release glaucoma medication, and corneal cross-linking. The addressable opportunity includes patients currently using conventional eye drops or surgical treatments, subject to clinical eligibility.
• Market Size: A consistently defined, independently verified combined dollar TAM for all current and prospective Glaukos franchises was not established. Management’s preliminary 2027 revenue objective of $1.00B provides a concrete commercialization benchmark but is not a TAM estimate.
• Market CAGR: No single market CAGR accurately represents the heterogeneous glaucoma and corneal franchises. Glaukos’s reported growth substantially exceeds what could reasonably be attributed to underlying patient-population growth alone.
• Commercial Expansion Opportunity: The largest incremental opportunity is greater penetration of established ophthalmology treatment markets through technology substitution, repeat utilization, and additional indications.
• Market Constraint: The theoretical patient population cannot be treated as fully addressable revenue because treatment eligibility, reimbursement, physician preferences, and procedural capacity constrain actual penetration.

Q2-A3. How Real Is Glaukos’s TAM? (Quality Check)

• Willingness to Pay: Chronic eye diseases can cause irreversible vision damage, creating substantial medical value for effective interventions. Payment remains dependent on payer coverage and reimbursement economics.
• Market Structure: The ophthalmology market includes large established competitors and specialized device manufacturers. Glaukos can achieve differentiated positions without controlling the entire market.
• Regulatory Entry Barriers: Pharmaceutical approvals, medical device authorization, clinical validation, and quality-system compliance impose substantial barriers.
• Commercial Validation: Q3 2026 revenue growth of 58% and corneal health growth of 154% demonstrate that treatment adoption is generating actual sales rather than remaining a purely theoretical market opportunity.
• Profit Potential: Q3 GAAP gross margin of approximately 85% indicates attractive product economics, although sales-force investment, research expenses, and reimbursement costs affect ultimate profitability.

Q2-A4. Can Glaukos Keep Expanding Its Market?

• Penetration Rate: The exact share of clinically eligible patients treated with iDose TR or Epioxa was not established. Rapid growth from a developing commercialization base suggests meaningful remaining penetration potential, but a numerical market-share claim would be unsupported.
• U.S. Expansion: Greater ophthalmologist adoption, repeat treatments where appropriate, expanded procedural use, and reimbursement optimization could increase revenue per treatment franchise.
• International Expansion: Established international glaucoma operations provide distribution relationships, although local regulatory approvals and reimbursement systems slow geographic replication.
• Product Portfolio Scalability: iDose TR, Epioxa, iStent, and pipeline products offer multiple opportunities to expand customer relationships.
• Marginal Cost Structure: Manufacturing, distribution, clinical support, and reimbursement administration create incremental costs. Glaukos cannot scale with near-zero marginal cost like a software platform.
• Long-Term Limitation: Rapid growth must eventually be supported by sustainable operating margins and returns on invested capital.

Q2-A5. Step 2 Key Takeaways

• Scoring Rationale:
  • Economic Moat (8/10): Proprietary ophthalmic technologies, regulatory approvals, clinical evidence, and surgeon relationships provide meaningful competitive differentiation, although substitutes remain available.
  • Market Size (4/5): Glaucoma and corneal disorders offer substantial commercial expansion opportunities, supported by accelerating sales, despite uncertain consolidated market sizing.
  • Market Quality·Profitability (6/7): High gross margins and clinically differentiated therapies indicate attractive unit-level economics, tempered by reimbursement and commercialization expenses.
  • Market Penetration·Scalability (6/8): Multiple product franchises and international distribution support expansion, while manufacturing requirements and physician adoption constrain scalability.
• 📊 Step 2 Score: 24/30 pts (Economic Moat 8/10 + Market Size 4/5 + Market Quality·Profitability 6/7 + Market Penetration·Scalability 6/8)
• Step 2 Summary: Glaukos combines substantial clinical differentiation with a favorable commercial expansion opportunity. Its defensibility is stronger than that of an undifferentiated device manufacturer, but it remains a capital- and execution-intensive healthcare business.

🚀 Step 3: How Fast Is Glaukos Growing? Hyper-Growth Metrics

Q3-A1. How Fast Is Glaukos Growing? (Revenue Trajectory)

• Accelerating Revenue Growth: FY2024 revenue was $383.48M, increasing 21.9% from FY2023. FY2025 revenue reached $507.44M, up 32.3%. Growth accelerated further to 50% YoY in Q2 2026 and 58% YoY in Q3 2026.
• Strong Sequential Expansion: Revenue increased from $185.61M in Q2 2026 to $211.03M in Q3 2026, representing approximately 13.7% QoQ growth. This followed strong prior-year comparisons and demonstrates continued commercialization momentum.
• J-Curve Position: Glaukos has entered a rapid commercialization phase in which newly launched therapies are becoming material contributors to consolidated revenue.
• Growth Drivers: iDose TR adoption, broader interventional glaucoma initiatives, and Epioxa commercialization are increasing revenue faster than the underlying ophthalmology market.
• Forward Trajectory: Management’s FY2026 revenue guidance midpoint of $780M implies approximately 53.7% growth from FY2025. Preliminary FY2027 revenue guidance of $1.00B implies approximately 28.2% additional growth.
• Acceleration Assessment: Historical annual and recent quarterly comparisons demonstrate genuine acceleration through Q3 2026. However, the preliminary 2027 outlook implies normalization from exceptionally high 2026 growth rather than indefinitely accelerating percentages.

Q3-A2. Glaukos’s Key Growth Metrics

• Selected Growth Indicators: Ophthalmic franchise revenue, treatment adoption, and commercialization milestones are more economically appropriate than subscription metrics because Glaukos earns revenue from medical devices and pharmaceutical therapies.
  • U.S. Glaucoma Revenue: Q3 sales increased 47% YoY to $118.60M, demonstrating sustained momentum in the largest franchise.
  • Corneal Health Revenue: Q3 sales increased 154% YoY to $59.00M, highlighting Epioxa-related expansion and strengthening portfolio diversification.
  • International Glaucoma Revenue: Sales rose 13.3% YoY to $33.36M, showing positive but slower growth than domestic operations.
• Pipeline Progress: iDose TREX, iDose TRIO, and additional ophthalmic development programs provide potential future expansion opportunities. Their commercialization timing and eventual contribution remain uncertain.
• Commercialization Validation: Growth across several franchises reduces dependence on a single product launch, although iDose TR and Epioxa remain crucial to the investment thesis.

Q3-A3. Are Glaukos’s Unit Economics Improving?

• Gross Margin Improvement: GAAP gross margin increased from approximately 78% in Q3 2025 to 85% in Q3 2026. Non-GAAP gross margin increased from approximately 84% to 88%.
• Operating Leverage: Q3 GAAP operating income improved from a $16.4M loss in 2025 to a $0.8M profit in 2026. Non-GAAP operating income improved from a $9.3M loss to a $27.3M profit.
• Expense Absorption: Quarterly revenue increased 58%, while R&D expenses grew approximately 26%. GAAP SG&A also increased 58%, reflecting continued commercialization investment.
• Rule of 40: Using approximately 53.8% expected FY2026 revenue growth and a 5.2% trailing FCF margin produces an indicative combined figure near 59%. This crosses the common 40% growth-and-cash-flow threshold, although that framework is less informative for medical technology than for recurring software businesses.
• Customer Economics: A reliable LTV/CAC ratio is not available because Glaukos does not disclose a subscription-style customer acquisition and retention model.
• Unit Economics Conclusion: Higher gross margins and positive quarterly operating income demonstrate improving economics, but durable profitability requires continued control of commercial spending.

Q3-A4. Step 3 Key Takeaways

• Scoring Rationale:
  • Revenue Growth Acceleration (11/12): Annual growth accelerated from approximately 22% in FY2024 to 32% in FY2025, followed by 50% and 58% quarterly growth in Q2 and Q3 2026.
  • Sector-Specific Growth Metrics (8/10): U.S. glaucoma and corneal health delivered strong franchise growth, supported by clinical differentiation, although adoption volumes are not fully disclosed.
  • Unit Economics·Margin (7/8): Gross margins expanded materially, and quarterly GAAP operating profitability emerged, but sustainable annual profitability remains unproven.
• 📊 Step 3 Score: 26/30 pts (Revenue Growth Acceleration 11/12 + Sector-Specific Growth Metrics 8/10 + Unit Economics·Margin 7/8)
• Step 3 Summary: Glaukos exhibits substantial, evidenced growth acceleration and improving operating economics. The main question has shifted from whether new products can generate demand to whether rapid commercialization can produce durable cash earnings.

💪 Step 4: Glaukos’s Profit Potential & Free Cash Flow

Q4-A1. Can Glaukos Turn Growth Into Profit?

• GAAP Profitability Inflection: Q3 2026 operating income of approximately $0.8M compares with a $16.4M operating loss one year earlier, indicating a meaningful improvement in operating leverage.
• Net Income Improvement: GAAP net income reached $2.0M, or $0.03 per diluted share, compared with a $16.2M loss, or $0.28 per share, in Q3 2025.
• Adjusted Earnings: Non-GAAP quarterly EPS improved to $0.47 from a loss of $0.16, demonstrating stronger operating performance after management-defined adjustments.
• Commercial Spending: Q3 SG&A of $130.9M and R&D of $48.1M remain significant relative to revenue. Continued revenue growth must offset these expenditures to sustain profitability.
• Annual Profitability Gap: Trailing twelve-month GAAP net income remained negative at approximately $169.80M despite the profitable latest quarter.
• Profitability Assessment: Glaukos has demonstrated a credible quarterly profitability inflection, but one positive quarter does not establish sustainable full-year GAAP profitability.

Q4-A2. Does Glaukos Generate Free Cash Flow?

• Trailing Cash Flow: Standardized trailing operating cash flow was approximately $47.71M, with capital expenditures of $11.69M, producing FCF of $36.02M.
• FCF Margin: Trailing FCF margin was approximately 5.2%, positive but modest compared with the company’s 81% trailing gross margin.
• Cash Conversion: Positive operating cash flow despite negative trailing GAAP earnings suggests that noncash expenses and working-capital effects materially influence reported profitability.
• Liquidity: Management reported approximately $339.8M of cash, short-term investments, and restricted cash at September 30, 2026, with no debt under its latest quarterly reporting basis.
• Self-Funding Potential: Positive FCF and substantial liquidity reduce immediate dependence on external equity issuance, although acquisitions, clinical development, and commercial expansion may increase capital requirements.
• Capital Efficiency: Trailing ROIC near -12.5% indicates that the company has not yet demonstrated sustained economic returns above its cost of capital.
• Financial Outlook: Future cash generation should improve if incremental revenue retains high gross margins while commercial and research spending grow more slowly.

Q4-A3. Step 4 Key Takeaways

• Scoring Rationale:
  • Operating Leverage·Path to Profit (7/8): Revenue growth and gross-margin expansion produced positive Q3 GAAP operating income, although annual GAAP profitability remains negative.
  • FCF·Capital Efficiency (5/7): Positive trailing FCF and substantial liquidity support reinvestment, but cash margins and ROIC remain below mature-company standards.
• 📊 Step 4 Score: 12/15 pts (Operating Leverage·Path to Profit 7/8 + FCF·Capital Efficiency 5/7)
• Step 4 Summary: Glaukos has crossed an important quarterly profitability threshold and generates positive trailing free cash flow. Sustained returns on invested capital remain the principal unfinished financial milestone.

👔 Step 5: Glaukos Management & Shareholder Alignment

Q5-A1. Who Leads Glaukos? (Founder & Management)

• Management Leadership: Thomas W. Burns has served as CEO since March 2002 and became chairman in December 2021. His long tenure provides continuity in ophthalmic product development and commercialization.
• Founder Status: Burns is not identified as an original founder of Glaukos, which was established in 1998. His subsequent leadership and industry experience nevertheless make him central to its commercial history.
• Strategic Vision: Management has consistently emphasized replacing conventional eye-care treatment approaches with proprietary interventional and sustained-release therapies.
• Guidance Execution: During 2026, management raised annual revenue guidance from $620M-$635M to $680M-$700M and subsequently to $775M-$785M.
• Execution Evidence: Record revenue growth, Epioxa commercialization, and improving operating margins support management’s credibility.
• Forward Credibility Test: The preliminary $1.00B 2027 revenue objective requires continued demand growth and effective execution across major franchises.

Q5-A2. Is Glaukos’s Management Aligned With Shareholders?

• Executive Equity Ownership: Reported insider ownership was approximately 3.6% of outstanding shares, providing some economic alignment but not controlling ownership.
• Insider Transactions: Recent ownership filings identify transactions involving Tomas Navratil, including filings in September and October 2026, and director Gilbert H. Kliman in August 2026. The complete transaction-level share counts and trailing twelve-month net open-market purchase/sale total could not be reliably reconstructed from the retrieved filings, so these transactions do not establish a directional insider-confidence signal.
• Shareholder Dilution: Shares outstanding increased approximately 2.9% YoY to 59.17M. Equity compensation and issuance therefore remain relevant to per-share value creation.
• Compensation Alignment: Equity-linked compensation can align executives with shareholders, but the economic benefit depends on performance conditions, grant dilution, and whether operating growth produces value per share.
• Governance Structure: No controlling dual-class voting structure was established for the listed common shares.
• Accountability Assessment: Management’s operational track record is favorable, while continued dilution and the difference between GAAP and adjusted earnings warrant monitoring.

Q5-A3. Step 5 Key Takeaways

• Scoring Rationale:
  • Founder Management·Vision (7/8): Long-serving leadership, differentiated product strategy, repeated guidance increases, and clinical execution provide strong evidence of credibility despite non-founder CEO status.
  • Alignment·Accountability (5/7): Insider equity ownership supports alignment, but measurable dilution and incomplete transaction-level evidence limit confidence in shareholder-value optimization.
• 📊 Step 5 Score: 12/15 pts (Founder Management·Vision 7/8 + Alignment·Accountability 5/7)
• Step 5 Summary: Glaukos benefits from experienced leadership with a substantial record of innovation and commercialization. Shareholder alignment is reasonable, although dilution and adjusted earnings require continued scrutiny.

⛵ Step 6: Glaukos Market Flow & Sentiment

Q6-A1. Analyst Consensus vs Glaukos Guidance

• Revenue Guidance: Management’s FY2026 revenue range of $775M-$785M has a midpoint of $780M.
• Consensus Alignment: Compiled FY2026 revenue expectations of approximately $780.5M closely match management’s guidance midpoint, indicating that the latest raised outlook is broadly incorporated into expectations.
• 2027 Revenue Outlook: Preliminary company guidance of approximately $1.00B is consistent with compiled next-year revenue expectations near $1.00B.
• Earnings Expectations: Compiled adjusted EPS expectations of approximately $0.64 for FY2026 and $1.40 for FY2027 indicate substantial anticipated earnings growth, but these measures differ from GAAP earnings.
• Analyst Sentiment: The compiled analyst recommendation remains predominantly bullish. Recent target revisions following Q3 results reflect greater confidence in commercial execution.
• Expectation Risk: After repeated guidance increases and a sharp share-price appreciation, future earnings releases may require continued positive surprises to sustain investor enthusiasm.

Q6-A2. What Is Glaukos’s Short Interest?

• Institutional Ownership: Reported institutional holdings represent approximately 103.9% of shares outstanding. Percentages above 100% can arise from reporting timing, overlapping filings, and share-lending mechanics and should not be interpreted as a literal fraction of unique shares.
• Short Interest: Approximately 4.34M shares were reported sold short.
• Short Percentage of Float: Approximately 7.61%, indicating meaningful but not extreme bearish positioning.
• Days to Cover: Approximately 4.37 trading days, suggesting that concentrated covering demand could amplify sharp positive price movements.
• Positioning Trend: Reported short shares increased from approximately 4.17M in the prior observation to 4.34M, indicating that short exposure remained meaningful despite strengthening fundamentals.
• Market Flow Interpretation: A relatively concentrated institutional shareholder base, moderate short interest, and recent high trading volume create conditions for elevated volatility around earnings and index rebalancing.

Q6-A3. Step 6 Key Takeaways

• Scoring Rationale:
  • Consensus vs Guidance (2/3): Management’s upgraded 2026 and preliminary 2027 revenue outlooks support favorable sentiment, but market expectations already reflect much of the improvement.
  • Supply·Short Interest (1/2): Moderate short interest and strong institutional participation provide potential momentum support while increasing the possibility of volatile reversals.
• 📊 Step 6 Score: 3/5 pts (Consensus vs Guidance 2/3 + Supply·Short Interest 1/2)
• Step 6 Summary: Analyst expectations have strengthened with operating performance. However, substantial recent appreciation and a demanding earnings outlook reduce the margin for disappointment.

🧨 Step 7: Glaukos Catalysts & Price Triggers

Q7-A1. What Could Re-Rate Glaukos Stock? (Next 12 Months)

• 1 Sustained iDose TR Commercial Expansion
  • Timing: Through 2027, particularly during quarterly earnings disclosures.
  • Success Conditions: Strong procedure adoption, favorable reimbursement, continued domestic glaucoma sales expansion, and evidence of repeat treatment opportunities.
  • Failure Risk: Slower physician adoption, reimbursement friction, product competition, or weaker treatment utilization.
• 2 Epioxa Commercialization and Broader Corneal Health Growth
  • Timing: Over the next 6-12 months as commercial adoption develops.
  • Success Conditions: Continued physician adoption supported by positive long-term clinical data, patient access, and insurance reimbursement.
  • Failure Risk: Slower treatment adoption, reimbursement constraints, or weaker-than-expected conversion from conventional procedures.
• 3 Progress Toward $1 Billion in 2027 Revenue
  • Timing: FY2026 results and subsequent 2027 quarterly disclosures.
  • Success Conditions: Management confirms its preliminary FY2027 outlook and demonstrates expanding operating margins and cash conversion.
  • Failure Risk: Revenue growth normalizes more quickly than expected or elevated commercialization expenses prevent sustained earnings improvement.

Q7-A2. Glaukos’s Estimate Revision Trend

• Revenue Estimate Direction: The FY2026 revenue outlook has risen materially following management’s successive guidance increases, with the latest compiled expectation near $780.5M.
• 2027 Expectations: The approximately $1.00B preliminary revenue objective has become the central benchmark for forward growth expectations.
• Earnings Revision Context: Q3 non-GAAP EPS of $0.47, compared with a year-earlier adjusted loss, supports a stronger profitability outlook.
• Revision Limitation: A complete dated 90-day numerical series of individual consensus revisions was not established. The confirmed upward management guidance trajectory and current compiled estimates provide directional evidence, rather than a precisely measured consensus revision percentage.
• Investment Implication: The fundamental estimate trend is favorable, but future revisions depend on continued execution rather than valuation expansion alone.

Q7-A3. Step 7 Key Takeaways

• Scoring Rationale:
  • Catalyst Strength (3/3): iDose TR expansion, Epioxa commercialization, and a clearly quantified 2027 revenue milestone provide multiple material catalysts.
  • Estimated Trend (2/2): Successive guidance increases and improving quarterly earnings support a positive forward-estimate direction.
• 📊 Step 7 Score: 5/5 pts (Catalyst Strength 3/3 + Estimated Trend 2/2)
• Step 7 Summary: Glaukos has several tangible catalysts tied to commercialization and operating profitability. The strongest evidence is management’s repeated revenue upgrades, although further upside depends on exceeding increasingly demanding expectations.

⚖️ Step 8: Is Glaukos Fairly Valued? Valuation Analysis

Q8-A1. Glaukos’s Key Valuation Multiples

• PS Ratio: 20.36x (very overvalued) — trailing revenue valuation incorporates substantial anticipated growth.
• P/FCF Ratio: 390.30x (very overvalued) — positive trailing FCF remains small relative to market capitalization.
• P/OCF Ratio: 294.67x (very overvalued) — operating cash generation has not yet caught up with market valuation.
• EV/Sales Ratio: 20.03x (very overvalued) — a substantial premium to revenue persists even after adjusting for net cash.
• EV/EBITDA Ratio: N/A (not applicable) — trailing EBITDA is negative, making the conventional positive-earnings interpretation unsuitable.
• EV/FCF Ratio: 383.87x (very overvalued) — enterprise value substantially exceeds current cash generation.
• Forward PE: 183.38x (very overvalued) — forward adjusted earnings are still small relative to the share price.
• PEG Ratio: N/A (unverifiable) — a sufficiently comparable earnings-growth denominator could not be established.
• Scoring Rationale: Glaukos commands substantial premiums across revenue, cash flow, and forward earnings. Strong growth and high gross margins offer partial justification, but current valuation assumes significant future scale and profitability.
• 📌 (1) Axis Q8-A1 Score: -5

Q8-A2. Glaukos vs Peers: Valuation Comparison

• Multiple selection based on peer comparison: EV/Sales is the preferred comparison because trailing GAAP profits remain distorted by commercialization and development investment. Relevant qualitative comparators include established ophthalmic manufacturers and high-growth specialist medical technology businesses, but their growth rates and product economics differ materially.
• Calculation of peer-to-peer deviation rate: N/A — an adequately reconciled current arithmetic mean across economically comparable peers was not established.
  • 🧮 Calculation Formula: ((Glaukos EV/Sales 20.03x - verified comparable peer mean) / verified comparable peer mean) × 100; the peer mean is unavailable, so no valid numerical deviation can be calculated.
• Scoring Rationale: Glaukos’s premium is evident in absolute valuation, but assigning a precise relative premium using unmatched mature-device and emerging-growth peers could misrepresent differences in revenue growth and margins. The relative axis remains unscored rather than imposing an unsupported comparison.
• 📌 (2) Axis Q8-A2 Score: 0

Q8-A3. What Is Glaukos Worth in the Future? (Forward Valuation)

• Implied Future Multiple: Using the preliminary FY2027 sales objective of $1.00B and current enterprise value of approximately $13.83B produces a current-value-to-FY2027-sales diagnostic of approximately 13.83x. At a judgment-based 10% annual required return, the two-year-equivalent future value hurdle is approximately 16.74x FY2027 sales, before additional interim cash-flow adjustments. The latter is a valuation hurdle at a common future date, not a forecast of Glaukos’s actual future enterprise value.
• Scoring Rationale: Even with the substantial revenue expansion already indicated for 2027, the market requires a high premium to future sales. High gross margins and potential operating leverage justify an above-average multiple, but commercialization spending, subsequent growth normalization, and dilution limit the sustainable premium. The comparison remains demanding against a judgmental 10x-14x forward-sales reference range for a high-growth, high-margin specialty ophthalmic franchise.
• 📌 (3) Axis Q8-A3 Score: -3

Q8-A3-1. What Growth Hurdle Does the Market Demand From Glaukos? (Forward Valuation Alternative)

• Scoring Rationale: Not applicable — the supported FY2027 revenue outlook and explicit forward valuation assumptions permit a primary future-valuation assessment.
• 📌 (3) Axis Q8-A3-1 Score: ➖

Q8-A4. Final Valuation Adjustment

• Scoring Rationale: No additional adjustment is warranted. The company’s clinical differentiation, regulatory approvals, product-launch execution, and margin expansion are already reflected in the operating and valuation analysis. The recent index change does not independently alter intrinsic value.
• 📌 (4) Axis Q8-A4 Score: 0

Q8-A5. Valuation Adjustment Score Calculation

• Calculation Process:
  • (1) Axis (Key Valuation Indicator): -5 pts (Very Overvalued)
  • (2) Axis (Peer-to-peer deviation rate): 0 pts (Numerical peer deviation unavailable)
  • (3) Axis (Justification of Growth): -3 pts (High forward-sales valuation requires substantial sustained operating improvement)
  • (4) Axis (Final adjustment): 0 pts (No additional independent factor)
• 📊 Valuation Adjustment Score: A1 (-5) + A2 (0) + A3 (-3) + A4 (0) = -8 pts
• Commentary: Glaukos’s fundamental improvements are substantial, but its present market valuation already capitalizes a large share of the anticipated commercialization success. The resulting valuation adjustment is negative because future execution must remain strong to justify the current premium.
• Step 8 Summary: Strong growth does not automatically translate into attractive entry valuation. Glaukos offers a compelling business trajectory but a narrow margin of safety at current prices.

💀 Step 9: What Are the Risks of Glaukos? Fatal Risks & Pre-Mortem

Q9-A1. Is Glaukos Burning Cash & Diluting Shareholders?

• Cash Burn: Trailing operating cash flow and FCF have become positive, reducing immediate funding risk.
• Liquidity Position: The company reported $339.8M in cash, short-term investments, and restricted cash at Q3 2026 and stated that it had no debt on its latest reporting basis.
• Cash Runway: A conventional cash-exhaustion runway is not currently a useful measure because trailing FCF is positive and liquidity remains substantial.
• Shareholder Dilution: Shares outstanding increased approximately 2.9% over the preceding year. This is measurable dilution but not evidence of an emergency capital raise.
• Potential Future Dilution: Equity compensation and any future acquisition-related issuance could reduce per-share benefits from operating growth.
• Funding Assessment: Glaukos does not currently display a verified near-term survival financing problem. Its principal financial risk is whether commercial spending and reinvestment can be converted into sustained positive returns.

Q9-A2. Do Competition or Regulation Threaten Glaukos?

• Competition: Large ophthalmic companies possess substantial distribution, research, and commercialization resources. Competitive devices and pharmaceutical therapies could reduce procedure growth or pricing flexibility.
• Reimbursement Regulation: Government and private payer coverage decisions directly influence treatment adoption, procedure economics, and physician willingness to offer Glaukos products.
• Clinical Safety: Implantable devices and pharmaceutical therapies face ongoing post-market safety monitoring. Unexpected complications could slow adoption or lead to regulatory intervention.
• Product Concentration: iDose TR and Epioxa are central to the growth outlook, making commercial setbacks in either franchise material.
• Regulatory Assessment: The latest product approvals and clinical results support the operating thesis. No verified regulatory prohibition threatening current core product sales was identified.

Q9-A3. Glaukos Pre-Mortem: What Could Go Wrong?

• 1 iDose TR adoption falls materially short of commercial expectations: Reimbursement friction or physician reluctance causes U.S. glaucoma growth to weaken, reducing operating leverage and undermining revenue objectives.
  • Early Warning Signal: Consecutive quarters of markedly slower U.S. glaucoma sales growth accompanied by reduced management guidance.
• 2 Epioxa adoption fails to convert clinical promise into sustainable revenue: Treatment access, payer coverage, or clinical workflow limitations constrain adoption despite favorable study outcomes.
  • Early Warning Signal: Corneal health revenue growth deteriorates while commercialization expenditure remains elevated.
• 3 High growth fails to produce durable economic profitability: Sales continue rising, but selling expenses, research investment, and competitive costs prevent sustained GAAP earnings and free cash flow improvement.
  • Early Warning Signal: Operating margins and FCF margins weaken despite continued substantial revenue growth.

Q9-A4. Risk Adjustment Score

• Reason for Scoring: Glaukos faces meaningful product-adoption, reimbursement, and commercial-execution risks, but the latest evidence shows accelerating revenue, improving profitability, positive trailing FCF, and substantial liquidity. Its major downside scenarios remain dependent on future deterioration rather than an established continuing impairment of the business model.
• 📊 Risk Adjustment Score: -4 pts
• Step 9 Summary: The company’s principal risks arise from execution and healthcare reimbursement rather than immediate financial distress. Current operating improvements provide meaningful mitigation, although continued monitoring is essential.

🎯 Step 10: Glaukos Final Verdict: Score & Rating

Q10-A1. Investment Score & Rating

• Investment Score Calculation Formula:
  • Step breakdown: S2 (24) + S3 (26) + S4 (12) + S5 (12) + S6 (3) + S7 (5) = 82 pts
  • Steps 2-7 Sum (82 pts) + Valuation Adjustment (-8 pts) + Risk Adjustment (-4 pts) = Investment Score 70 pts
• Investment Score & Rating: 70 pts (B Rating ⭐⭐⭐)
  • Commentary: Strong commercialization, accelerating sales, expanding gross margins, and improving cash generation establish an attractive fundamental growth profile. However, substantial valuation premiums and continued dependence on reimbursement and launch execution limit the attractiveness of immediate entry.

Q10-A2. Should You Buy Glaukos? (Recommendation)

• Recommendation: Hold
  • Commentary: Glaukos has established credible momentum across multiple ophthalmic treatment franchises, with improving profitability and favorable clinical evidence. Nevertheless, the stock’s elevated valuation already anticipates substantial further growth, making disciplined entry prices important for prospective investors.

Q10-A3. Investment Thesis in One Line

• Glaukos combines accelerating ophthalmic treatment adoption, differentiated clinical technology, and emerging profitability, but its premium valuation leaves limited room for commercialization or earnings disappointments.

Q10-A4. Glaukos’s Price Trend & Key Drivers

• Stock Price Trend Over the Past 12 Months: Strong Upward Trend 📈 — Shares gained approximately 172% over the preceding year through October 30, 2026, reflecting significant commercialization progress, repeated guidance increases, and a sharp late-October rally.
• July 29, 2026 Q2 Revenue Growth and Guidance Increase
  • Description: The company reported 50% revenue growth and raised annual guidance to $680M-$700M, reinforcing expectations for accelerating commercial adoption.
  • Stock Price Reaction: Broader Upward Momentum 📈 — Shares continued appreciating across the subsequent months as commercialization expectations strengthened; the broader advance cannot be attributed exclusively to this announcement.
• October 07, 2026 Positive Three-Year Epioxa Clinical Results
  • Description: Long-term clinical evidence supported the treatment’s durability and clinical differentiation.
  • Stock Price Reaction: Volatile Response 📈↘️ — Shares closed at approximately $172.18 on October 7 and $161.29 on October 8, showing a sharp reversal over the following session despite favorable clinical news.
• October 28, 2026 Q3 Earnings Beat and Major Guidance Upgrade
  • Description: Record quarterly revenue, positive GAAP net income, increased FY2026 guidance, and preliminary FY2027 revenue guidance of $1.00B materially strengthened the growth narrative.
  • Stock Price Reaction: Sharp Rise 📈 — Shares closed at $181.43 on October 28 and surged 33.65% to $242.48 on October 29 before easing to $237.60 on October 30.

Q10-A5. Action Plan

• Current Price: $237.60
• Buy Zone: $180.00 ($175.00–$185.00)
  • (1) Calculation of Fundamental Value: A conservative entry range is established below the base-case forward valuation, providing a safety margin against slower treatment adoption and future margin uncertainty.
  • (2) Momentum Premium/Discount Application: Strong commercial momentum and an improving earnings profile justify maintaining exposure to the growth opportunity, but the exceptional late-October rerating argues against paying an unrestricted momentum premium.
  • (3) Conclusion: The $175.00-$185.00 range, with a $180.00 midpoint, provides an approximately 14% discount to the base-case target while remaining consistent with the stock’s pre-earnings trading region. The zone is a valuation-based entry preference rather than a confirmed durable technical support level.
• Price Target: $208.45
• Expected Return: -12.3% (vs. current price)
  • 📍 Selected Valuation Metric: FY2027 EV/Sales — a forward revenue multiple is appropriate because Glaukos is transitioning toward sustainable GAAP profitability and has explicit preliminary FY2027 revenue guidance.
  • 🧮 Price Target Calculation Formula: (($1.00B FY2027 revenue × 12.0x EV/Sales + $0.34B net cash) / 59.20M shares) = $208.45
  • ⚓ Valuation Basis and Key Assumptions: The base case uses management’s preliminary $1.00B FY2027 revenue outlook and an independently selected 12.0x forward EV/Sales multiple within a judgmental 10x-14x range for high-growth specialty ophthalmic franchises. The multiple reflects high gross margins and expected operating leverage, while allowing for slower growth after the 2026 acceleration, ongoing commercialization spending, and reimbursement risk. The model assumes approximately $340M net cash and 59.20M shares without major future issuance. This target is below the current quote because the market’s recent rerating prices more aggressive long-term margin and franchise durability assumptions than this base case; changes in sustainable operating margins or the justified sales multiple could materially alter the estimate.
• Conditions and timing for reaching price target: Over the next 6-12 months, the target depends on FY2026 results confirming the upgraded revenue outlook and subsequent 2027 disclosures showing sustainable profitability. Continued rapid adoption could justify a higher multiple, whereas slowing growth could produce a more pronounced repricing.
• Stop Loss: $148.00 ($144.00–$152.00)
• Action trigger upon catalyst achievement:
  • 1 FY2026 revenue meets or exceeds the $785M guidance ceiling
    • Description: Assess whether upside reflects recurring product demand and whether 2027 revenue expectations can rise without disproportionate spending. 👉 Maintain Holdings (Hold)
  • 2 Epioxa commercialization substantially exceeds expectations
    • Description: Evaluate whether stronger corneal health sales translate into sustained gross margin and operating profit improvement before reassessing intrinsic value. 👉 Reassess Valuation (Hold)
  • 3 GAAP operating profitability remains positive across successive quarters
    • Description: Sustainable earnings and cash conversion would strengthen the long-term investment case, potentially supporting additional exposure at attractive valuations. 👉 Consider Buying at Attractive Prices (Buy)
• Action trigger upon risk realization:
  • 1 U.S. glaucoma sales growth weakens materially for consecutive quarters
    • Description: Deteriorating core franchise demand would challenge the principal growth assumptions and warrant reassessment of the forward valuation. 👉 Reduce Holdings (Sell)
  • 2 Reimbursement restrictions materially reduce treatment adoption
    • Description: Reduced patient access or physician economics could impair the long-term commercial opportunity. 👉 Reduce Holdings (Sell)
  • 3 Revenue remains strong but sustained profitability disappears
    • Description: A persistent failure to convert sales growth into operating cash flow would weaken the investment thesis. 👉 Reassess Holdings (Hold)
• Customized Strategy Guide by Investment Preference:
  • Defensive Investors: Avoid initiating a full position at the current premium valuation. Consider a limited allocation only when the share price approaches the valuation-based Buy Zone and operating fundamentals remain intact.
  • Neutral Investors: Maintain existing exposure while monitoring commercialization, revenue guidance, and cash-flow conversion. Favor incremental purchases near the established entry range rather than chasing earnings-driven rallies.
  • Aggressive Investors: Small tactical positions may be considered around meaningful corrections, but position sizing should reflect the possibility of substantial multiple compression even if revenue continues growing.

🕵️‍♂️ Deep Dive Analysis

Q1: Is Glaukos’s Dependence on iDose TR and Epioxa Commercialization Its Biggest Weakness?

• Analysis: Glaukos’s strongest growth drivers are also important sources of concentration risk. iDose TR adoption and Epioxa commercialization explain much of the company’s recent growth acceleration and market enthusiasm. If either franchise fails to achieve expected procedure volumes, the company may face slower revenue growth while retaining a substantial commercial infrastructure. The risk is amplified by the need for continuing physician education, reimbursement support, and clinical acceptance. Nevertheless, both franchises have already generated meaningful commercial results, and the broader glaucoma portfolio offers additional revenue support.
• Judgment: Neutral — Product concentration is material, but demonstrated sales growth, clinical evidence, and multiple established product lines reduce the likelihood that one setback would immediately invalidate the entire business.

Q2: Can Glaukos’s Premium Forward Sales Valuation Be Justified by Its Ophthalmic Growth Opportunity?

• Analysis: Glaukos trades at approximately 20.36x trailing sales and 13.83x management’s preliminary FY2027 revenue objective on a current enterprise-value basis. Sustaining these valuation levels requires substantial operating margin expansion and continued growth beyond 2027. A high gross margin provides an economic foundation for future profits, but commercial spending, development expenditure, and potential dilution reduce cash conversion. A premium can remain rational if Glaukos develops into a high-margin ophthalmic platform with durable product franchises. However, a 12.0x sales multiple applied to the 2027 objective produces an independently constructed valuation below the present share price.
• Judgment: Overvalued — The company’s growth and product differentiation are substantial, but the current price embeds more optimistic long-term profitability assumptions than the base case.

Q3: Can Glaukos Sustain Its 2026 Revenue Acceleration After Reaching $1 Billion in 2027 Sales?

• Analysis: Glaukos’s annual growth accelerated from approximately 22% in FY2024 to 32% in FY2025, followed by 58% YoY growth in Q3 2026. The preliminary $1.00B FY2027 outlook implies growth of approximately 28% from the FY2026 guidance midpoint. This represents a natural normalization from an exceptionally strong commercialization phase rather than evidence of an immediate decline in demand. Sustaining attractive growth beyond 2027 will require additional penetration of glaucoma treatment markets, broader Epioxa adoption, and potentially new products or indications.
• Judgment: Positive — The company has credible medium-term growth drivers, although investors should expect percentage growth to normalize as the revenue base expands.

Q4: Will Glaukos’s 85% Gross Margin Translate Into Sustainable GAAP Profitability?

• Analysis: Q3 2026 GAAP gross margin reached approximately 85%, compared with 78% one year earlier. Revenue increased 58%, allowing GAAP operating income to improve from a $16.4M loss to a $0.8M profit. The operating leverage is meaningful, but SG&A and R&D remain substantial. Sustained profitability depends on treatment volumes expanding without proportional increases in commercial and research expenditures. Adjusted profits provide supplementary evidence but should not replace the GAAP profitability test.
• Judgment: Positive — The quarterly profitability inflection is supported by actual operating results, although the next several reporting periods must establish its durability.

Q5: Could Glaukos’s iDose TR Platform Meaningfully Disrupt Conventional Glaucoma Eye Drops?

• Analysis: Traditional glaucoma medications often depend on consistent daily patient administration. iDose TR offers sustained pharmaceutical delivery directly inside the eye, potentially reducing adherence problems. The platform’s economics depend on treatment effectiveness, duration, patient selection, reimbursement, and physician adoption. The January 2026 labeling expansion permitting re-administration in eligible patients strengthens the possible lifetime treatment opportunity. However, conventional drops remain inexpensive and familiar, while alternative sustained-delivery approaches may emerge.
• Judgment: Positive — iDose TR addresses an established clinical problem through a differentiated mechanism, but its commercial ceiling depends on access and adoption rather than technology alone.

Q6: Can Glaukos’s Epioxa Become a Leading Treatment for Keratoconus?

• Analysis: Epioxa’s epithelium-on approach removes a major procedural burden associated with traditional epithelium-off corneal cross-linking. FDA approval and subsequent long-term clinical results provide evidence supporting the technology. Corneal health revenue increased 154% YoY in Q3 2026, demonstrating strong commercial momentum. Nevertheless, treatment adoption depends on physician training, reimbursement, patient identification, and long-term real-world outcomes. Clinical differentiation does not eliminate competing treatment pathways.
• Judgment: Positive — Epioxa has meaningful clinical and commercial advantages, with early revenue growth supporting the opportunity. Long-term market penetration remains to be established.

Q7: Does Glaukos Have Enough Financial Strength to Fund Its Ophthalmic Pipeline Without Major Shareholder Dilution?

• Analysis: At the end of Q3 2026, management reported approximately $339.8M in cash, short-term investments, and restricted cash, with no debt under the latest reporting basis. Positive trailing FCF further reduces dependence on external financing. However, share count increased approximately 2.9% YoY, showing that equity dilution remains relevant even without emergency financing. Clinical programs, new commercial launches, and potential acquisitions may require additional funding.
• Judgment: Positive — Current liquidity and cash generation support continued development investment without a clearly established near-term financing crisis, although per-share dilution warrants monitoring.

Q8: How Much Could Reimbursement Changes Affect Glaukos’s Glaucoma and Corneal Treatment Franchises?

• Analysis: Reimbursement is a critical commercial variable because physicians and patients are sensitive to the economic accessibility of treatment. Favorable reimbursement can accelerate adoption of iDose TR and Epioxa, while restrictive coverage, payment reductions, or administrative burdens may limit procedure volumes even when clinical evidence remains favorable. Glaukos’s medical and pharmaceutical franchises face different coverage mechanisms, creating both diversification and administrative complexity. Investors should monitor changes in reimbursement policy alongside reported sales and procedure adoption.
• Judgment: Neutral — Reimbursement creates meaningful uncertainty, but existing commercial growth indicates that access barriers have not prevented substantial adoption.

Q9: Could Glaukos’s Strong Institutional Ownership and Short Interest Amplify Stock Volatility?

• Analysis: Reported institutional ownership exceeds 100% because ownership reporting and share-lending conventions can produce overlapping observations. Approximately 7.61% of the float is sold short, with an estimated 4.37 days to cover. These figures indicate that covering activity can amplify positive surprises, while highly concentrated expectations can intensify selling after disappointments. The 33.65% share-price surge on October 29, 2026, illustrates the magnitude of potential price movements around significant earnings announcements. The precise share of that move attributable to short covering cannot be established.
• Judgment: Neutral — Market positioning can magnify volatility but does not independently establish long-term intrinsic value.

Q10: What Must Glaukos Demonstrate to Become a Durable Long-Term Healthcare Compounder?

• Analysis: Glaukos must demonstrate that strong revenue growth can translate into sustained GAAP operating profits, improving FCF margins, and positive economic returns on invested capital. Maintaining high gross margins while controlling SG&A and R&D is essential. The company also needs continued clinical differentiation, favorable reimbursement, and successful commercialization of new therapies. Revenue approaching the preliminary $1.00B FY2027 objective would establish scale, but durable value creation requires improving per-share cash generation rather than revenue growth alone. The strongest long-term scenario involves several product franchises generating recurring procedural demand with progressively lower incremental operating costs.
• Judgment: Positive — Glaukos has established substantial elements of a differentiated ophthalmic treatment platform, but its transition into a durable compounder remains incomplete until profitability, cash conversion, and capital efficiency improve consistently.